GILD · 8-K · 20261029PR000037

Acquisition-Related R&D Charges

GILEAD SCIENCES, INC. · 2026-10-29 · Importance 93 · Surprise 82 · In source text

Gilead’s full-year 2026 guidance includes approximately $12.4 billion of acquired IPR&D charges related to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions, net of the Lakefront collaboration and related taxes. The charges contribute approximately $9.88 of the projected full-year diluted loss per share. Nine-month acquired IPR&D expense was $11.307 billion, compared with $485 million in the prior-year period, and nine-month IPR&D impairments added $1.750 billion. Gilead also announced a definitive agreement to acquire PepStar’s oral IL-23R inhibitor program, including Phase 1 asset HCXT-2001; the release did not disclose a transaction price.

Key facts

• Gilead’s 2026 GAAP and non-GAAP diluted loss per share guidance includes an approximately $9.88 per-share impact from $12.4 billion of acquired IPR&D charges related to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions announced in 2026, net of the Lakefront collaboration impact and related taxes. source
• Gilead’s acquired IPR&D expenses were $18 million in the third quarter of 2026. source

Impact estimates